2024 World Conference on Lung Cancer (WCLC) - Posters-P3.01E.01 Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk in Treatment-Naïve Type 2 Diabetes: Potential Impact of Obesity and Gender

P3.01E.01 Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk in Treatment-Naïve Type 2 Diabetes: Potential Impact of Obesity and Gender

Back to course

Pdf Summary

This study investigates the impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1a) on lung cancer risk in treatment-naïve patients with Type 2 diabetes mellitus (T2DM), considering the potential influence of obesity and gender. The research utilizes a global big data source from the TriNetX Global Collaborative Network, encompassing patients who began antidiabetic medication between 2010 and 2019. Key criteria included adult T2DM patients with no prior diagnosis of lung cancer or solitary pulmonary nodules.<br /><br />The study employs propensity score matching to balance demographics, comorbidities, BMI, and HbA1c levels between GLP-1a users and non-users. The primary outcome measured was the incidence of lung cancer over a 15-year follow-up. GLP-1a users were compared both to those initially using other diabetes medications and to those using medications other than GLP-1a.<br /><br />Findings suggest that GLP-1a usage is associated with a reduced risk of developing lung cancer among treatment-naïve T2DM patients. Demographic data showed minor differences between the GLP-1a cohort and the non-GLP-1a cohort, with slightly higher nicotine dependence and COPD prevalence noted in the GLP-1a users. However, gender distribution, age, and racial makeup were similar across both cohorts.<br /><br />This research builds on existing studies indicating that GLP-1a could contribute to reduced risks of certain obesity-associated cancers, without increasing risks for thyroid or pancreatic cancers. The implication of these findings is significant, as they support the potential protective role of GLP-1a in lung cancer risk management for diabetic patients, especially against the backdrop of concerns about cancer risks associated with antidiabetic therapies. Further research may delve deeper into the biological mechanisms behind this association.

Asset Subtitle

Junmin Song

Meta Tag

Speaker Junmin Song

Topic Risk Factors, Risk Reduction & Tobacco Control

Keywords

GLP-1a

lung cancer risk

Type 2 diabetes

obesity influence

gender influence

TriNetX Global Collaborative Network

propensity score matching

antidiabetic medication

cancer risk management

biological mechanisms